What caught my attention was the cardiovascular research
Conflict of interest JT has given Scientific advice to AlfaWassermann, Allergan, Christian Hansen, Danone, Grnenthal, Ironwood, Janssen, Kiowa Kirin, Menarini, Mylan, Neutec, Novartis, Noventure, Nutricia, Shionogi, Shire, Takeda, Theravance, Tramedico, Truvion, Tsumura, Zealand, and Zeria pharmaceuticals and has served on the Speaker bureau for Abbott, Allergan, AstraZeneca, Janssen, Kyowa Kirin, Menarini, Mylan, Novartis, Shire, Takeda, Truvion, and Zeria
Unfortunately, given the costs that go into clinical trials and the fact that potentially hundreds of thousands of people are already taking these peptides (so theres already a market driving profit), theres a strong possibility that a new robust clinical trial may never be done on BPC-157
[PMID: 8678536] PubMed record related to this compound for laboratory literature review